Close your eyes and imagine a health care system that truly prioritizes patients above all else, one that is free from political interference, financial incentives, or secondary gains that distort decision-making. In this ideal framework, regulatory bodies such as the Medical Board, Centers for Disease Control and Prevention (CDC), and Drug Enforcement Administration (DEA) would enforce guidelines uniformly and based on evidence, without inadvertently inflating costs or compromising care quality for patients, providers, and the system as a whole.
To elaborate, drawing from extensive studies, reports, and expert analyses, the core problem lies in how prioritizing political or enforcement agendas over genuine patient needs undermines systemic efficiency and equity.
The regulatory burden
Stringent regulations on controlled substances, particularly opioids, were introduced with the noble intent of mitigating misuse and addiction. However, the 2016 CDC opioid prescribing guidelines, while aimed at curbing overprescribing, have inadvertently created barriers to appropriate pain management. Patients with chronic pain, cancer, or other legitimate needs often face restricted access to effective treatments, forcing physicians to pivot to less optimal alternatives that may carry higher risks or reduced efficacy.
This shift has not consistently achieved the anticipated cost reductions and has instead contributed to patient suffering and fragmented care. A detailed examination in a March 2023 article by Sam Whitehead and Andy Miller, published in KFF Health News, highlights how these guidelines have left many patients underserved, exacerbating their conditions without proportionally addressing the opioid crisis.
Compounding this, DEA enforcement mechanisms impose additional hurdles, such as stringent monitoring and penalties for perceived noncompliance, which deter providers from prescribing necessary medications. This regulatory burden escalates administrative overhead, invites fines, and fosters a culture of hesitation among clinicians, ultimately inflating health care expenses through indirect channels like increased litigation fears and operational inefficiencies.
The prosecutorial mindset
A particularly troubling dimension involves state medical boards, which often collaborate with attorneys general (AGs) as prosecutors in disciplinary actions. In many jurisdictions, medical boards refer cases to the AG’s office for formal accusations and prosecutions, granting prosecutors significant latitude in pursuing charges. This setup can lead to what critics describe as “creative” or overzealous prosecution: strategies where AGs prioritize securing convictions at all costs, sometimes expanding initial complaints into broader allegations or pursuing marginal cases aggressively to avoid perceived losses.
Such approaches disregard the nuanced context of medical practice and can morph minor issues into protracted legal battles. This prosecutorial mindset, often driven by political pressures or resource constraints, weakens the health care system by instilling fear among physicians, leading to high burnout rates and workforce attrition.
For example, a 2006 report from the U.S. Department of Health and Human Services on state discipline of physicians notes that prosecutorial staff, frequently housed within AG offices, handle preparations and hearings with a focus on strategy that can escalate costs and deter settlement. The report highlights how high litigation expenses, sometimes exceeding $100,000 per case, and considerations like impacts on rural access or pain management are often sidelined.
Recent trends in physician prosecutions, particularly around opioid prescribing, underscore this overreach. A January 2025 analysis from Safe Harbor Group argues that prosecutorial tactics have scared away qualified professionals, exacerbating the opioid crisis by limiting access to legitimate treatments and weakening the health care workforce.
The cost of fear
Collectively, these enforcement patterns contribute to systemic vulnerabilities: Over half of physicians report burnout from regulatory overload, per various surveys, leading to higher turnover and reduced service availability. This, in turn, elevates costs as patients seek care through more expensive channels like emergency departments.
Yet, optimism must be tempered by frustration over uneven enforcement driven by financial or political motives. Physicians increasingly resort to “defensive medicine,” ordering superfluous tests or procedures to mitigate litigation risks, ballooning U.S. health care costs by $46 billion to $300 billion annually, equating to 2 percent to 9 percent of total spending. This fear stems not from patient needs but from potential investigations, further straining resources.
A better way forward
In stark contrast, reorienting toward a patient-centered model, where care is individualized, emphasizing open communication, shared decision-making, and preventive strategies, yields measurable benefits. Research demonstrates that such approaches enhance health outcomes, including improved quality of life and fewer hospital readmissions, while reducing overall expenditures by approximately 9 percent in targeted studies.
Selective enforcement by medical boards exacerbates this, targeting conscientious providers with disproportionate scrutiny while overlooking systemic loopholes. These oversight entities often escape accountability, and challenging them can intensify conflicts, prioritizing point-proving over resolution.
Rather than deterring entry into medicine amid existing shortages, we must advocate for reform: refocusing on patient-doctor partnerships, adopting evidence-driven models that trim inefficiencies, and holding regulators to standards that bolster, rather than burden, the system. By doing so, we can foster a healthier, more equitable health care landscape for all.
Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.
Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.
Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.
